Overview

A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Primary Insomnia

Status:
Completed
Trial end date:
2008-05-07
Target enrollment:
Participant gender:
Summary
Patients with Primary Insomnia will be treated with GW597599 and GR205171 to evaluate the efficacy in the sleep difficulties associated with insomnia
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Vestipitant
Vofopitant